Printer Friendly

ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES FDA PERMISSION TO BEGIN MARKETING SAT PAD(TM)

    SAN DIEGO, Nov. 16 ~PRNewswire~ -- Alliance Pharmaceutical Corp . (NASDAQ: ALLP) announced that the U.S. Food and Drug Administration (FDA) has notified the company that it can commence marketing Sat Pad(TM), an external device for use with magnetic resonance (MR) imaging.
    Sat Pad is a kit consisting of anatomically conforming pads that are filled with perfluorochemical.  The pads can be positioned externally over difficult-to-image areas of anatomy to improve MR fat saturation techniques, which are used to saturate or nullify the unwanted signals generated by fatty tissues and fat-containing bone marrow during the MR imaging process.  These techniques are marginally successful in imaging certain areas of the body, such as the neck, ankle or knee.  The Sat Pad product aids in creating better images of these areas.
    Alliance submitted a 510(k) premarket notification for Sat Pad to the FDA in August 1992.  The kits will be marketed to the approximately 3,000 centers with MR scanners in the United States. The company estimates that the product has the potential to generate revenues of approximately $20 million over the next four to five years.
    Alliance is a leader in the development of proprietary medical products based upon perfluorochemical and emulsion technologies.  The company's efforts focus on two primary areas: diagnostic contrast agents for use with major imaging modalities to aid in the early diagnosis of certain cancers and other pathological conditions; and oxygen carriers for use as a temporary red blood cell substitute and as adjunctive treatments of various cardiovascular, cancer and respiratory conditions.
    -0-             11~16~92
    CONTACT:  Stuart Gauld of Alliance Pharmaceuticals, 619-558-4300
    (ALLP) CO:  ALLIANCE PHARMACEUTICALS CORP. IN:  MTC ST:  CA


-- SD003 -- X159 11~16~92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1992
Words:280
Previous Article:DELMARVA POWER RECEIVES PHILANTHROPY AWARD
Next Article:NEW DESIGNCAD 2D VERSION 6.0 COMPLETELY REWRITTEN
Topics:


Related Articles
AMYLIN PHARMACEUTICALS ANNOUNCES FDA PERMISSION TO BEGIN CLINICAL TESTING
SCICLONE PHARMACEUTICALS ANNOUNCES APPROVAL TO BEGIN CLINICAL TRIALS IN JAPAN FOR THYMOSIN ALPHA 1
ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES MARKETING APPROVAL FOR IMAGENT(R) GI
CIBA VISION OPHTHALMICS FORMS STRATEGIC ALLIANCE WITH AUTONOMOUS TECHNOLOGIES CORPORATION
ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES LICENSING AGREEMENT WITH ORTHO BIOTECH INC./R.W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
ImaRx Pharmaceutical Corp. Announces Plans for Expansion; New Vice President, Groundbreaking, Clinical Drug Trials
Alliance Pharmaceutical Corp. Announces Submission of 510(K) Application For the RODA(R) Patient Monitoring System.
Alliance Pharmaceutical Corp. Announces Completion of Private Placement Financing.
Alliance Pharmaceutical Corp. Announces American Society of Hematology Publication Demonstrating Oxygent(TM) Reduces Sickle Cell Blood Vessel...
ALLIANCE PLANS EUROPEAN PHASE 3 STUDY FOR OXYGENT.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters